Neurol. praxi. 2018;19(4):279-283 | DOI: 10.36290/neu.2018.107
The treatment of severe pain which does not react to nonopioid analgesic drugs
- Centrum pro léčbu bolesti a paliativní medicínu, s. r. o., Zlín
Pain is subjective perception a and the effective management of chronic pain is fundamental goal for the people , who treat thepain. Chronic pain is describe like two basic kinds of pain – nociceptive and neuropathic pain., wich appears separatly or in combination.The World Health Organisation (WHO) developer outlines the tree-step analgesic lader these opioids in the managementof cancer pain, and these are widely accepted and extensively validated guidelines heve been influential in the aplplication ofopioidy therapy for treatment of chronic, non-malignant pain.The morfin is the main representative such potent opioids and plays an important role in management of pain in patients withchronic pain in paliative care. The newer- generation agents –fentanyl, buprenorfin, oxycodon, hydromorfon and tapentadolplays important role in chronic, non malignant pan.New opioid tapentadol is the first compoud of new pharmacological class MOR-NRI, that combines mi-opioid-agonist and noradrenalinre-uptake inhibitor activities in one molecule.
Keywords: opioids drugs, fentanyl, buprenorfin, oxycodon, tapentadol, gabapentinoids drugs
Published: September 1, 2018 Show citation
References
- Attal N, Cruccu G, Baron R, Haanpaa M, Hansson P, Jensen TS, Nurmko T. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010; 17: 1113-1123.
Go to original source... 
Go to PubMed... - Busse JW,Craigie S, Juurlink DN, Buckley DN, Wang L, Couban RJ, Agoritsas T, Akl EA, Carrasco-Labra A, Cooper L, Cull C, da Costa BR, Frank JW, Grant G, Iorio A, Persaud N, Stern S, Tugwell P, Vandvik PO, Guyatt GH. Guideline for opioidy therapy a and noncancer pain. CMAJ 2017; 189(18): E659-E666. Go to original source... Go to PubMed...
- Eissenberg E, Mc Nicol ED, Car DB. Efficacy of mi-opioid agonist in treatment of evoked neuropathic pain: systematic review of randomized controlled trials. Eur J Pain 2006; 10: 667-676. Go to original source... Go to PubMed...
- Kršiak M. Dávkování paracetamolu u dospělých s ohledem na hmotnost a kinetiku: simulace na počítači. Bolest 2011; 14(1): 23-28.
- Kršiak M. Novinky ve farmakologii opioidů s významem pro praxi. Paliat med léčba bolesti 2010; 3(1): 28-30.
- Metodické pokyny pro farmakoterapii bolesti - Bolest-supplementum. 2016; 1: 8-9.
- Metodické pokyny pro farmakoterapii bolesti - speciální část. Bolest - supplementum 2017; 1: 8-13.
- Reviiere PJ. Peripheral kappa-opioid agonist for visceral pain. Br J Pharmacol 2004; 141: 1331-1334. Go to original source... Go to PubMed...
- Rokyta R, Kršiak M, Kozák J. Bolest. Tigis, přepracované doplněné vydání 2012; 24: 250.
- Rowbotham MC, Twilling L, Davies PS, Reisner L, Taylor K, Mohr D. Oral opioidy therapy for chronic peripheral and central neuropathic pain. N Engl J Med 2003; 348(13): 1223-1232. Go to original source... Go to PubMed...
- Staal C, Dimcevski AM, Anderson SD, Arendt-Nielsen L, Drewes AM. A comparative study of oxycodone and morfine in multimodal tissue differented experimental pain model. Pain 2006, 123: 28-36. Go to original source... Go to PubMed...